Press releases
- BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
- BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
- BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
- BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
- BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
- BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
- BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
- BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
- BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
More ▼
Key statistics
On Friday, Brainstorm Cell Therapeutics Inc (GHDN:FRA) closed at 0.4865, 350.46% above the 52 week low of 0.108 set on Nov 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.4865 |
---|---|
High | 0.4865 |
Low | 0.4865 |
Bid | 0.472 |
Offer | 0.516 |
Previous close | 0.498 |
Average volume | 1.67k |
---|---|
Shares outstanding | 68.34m |
Free float | 59.28m |
P/E (TTM) | -- |
Market cap | 36.53m USD |
EPS (TTM) | -0.4079 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:13 BST.
More ▼